Froedtert & The Medical College of Wisconsin
FroedtertHealth
In Wisconsin, call
1-800-DOCTORS
Contact Us | News Room | Careers
For Professionals | For Employers
  • Froedtert Health Home
  • Froedtert
    Hospital
  • Community Memorial
    Hospital
  • St. Joseph's
    Hospital
  • Community &
    Specialty Clinics
Froedtert & The Medical College of Wisconsin
Find a Doctor
Diseases and Specialties
Locations & Directions
Patient Information
Visitor Information
Clinical Research
Donating and Volunteering
For Health Care Professionals
Health Resources
About Us
Diseases and Specialties Home
Directions to Campus
On-Campus Directions
Off-Campus Facilities
Froedtert Health Locations
Primary Care Clinics
Centers for Diagnostic Imaging (CDI)
New Clinics & Relocations
Transportation and Parking Services
Advance Directives
Appointments
Billing and Insurance
Contacting a Patient
Find a Doctor
Gift Shop
Inpatient Care
Medical Records
Patient and Family Services
Patient Safety
Pharmacy
Pre-Arrival
Privacy
CarePages
Contacting a Patient
Hours and Guidelines
Local Area Services
Services in the Hospital
Current Programs
Clinical Trials Basics
Translational Research Units
Recommended Resources
Froedtert Hospital Foundation
Volunteering
About Nursing
For EMS
For Physicians
Professional Education
Child Life Services
Classes and Events
e-Newsletters
Griefwords
Health Care Roundtable
Health Blogs
Health Podcasts
Just Drive!
Reading Room
Small Stones Wellness Center
Support Groups
Workforce Health Program
Academic Medical Center
Achievements and Recognition
Advanced Practice Nurses
For Our Suppliers
Our Commitment to Community
Our Physicians
Our Prices
Partnerships and Affiliations
Physician Assistants
Quality Care
Who We Are
Working at Froedtert
Home ) Clinical Research ) Current Programs ) Cancer Clinical Trials ) Hematologic Cancer Clinical Trials
Picture of researcher
Clinical Research
Current Programs
Cancer Clinical Trials
Bone and Soft Tissue Cancer Clinical Trials
Brain Cancer Clinical Trials
Breast Cancer Clinical Trials
Gastrointestinal Cancer Clinical Trials
Genitourinary Cancer Clinical Trials
Gynecology Cancer Clinical Trials
Head and Neck Cancer Clinical Trials
Hematologic Cancer Clinical Trials
Liver, Pancreas and Biliary Cancer Clinical Trials
Miscellaneous Cancer Clinical Trials
Skin Cancer Clinical Trials
Thorax and Chest Cancer Clinical Trials
Heart and Vascular Clinical Trials
Neurosciences Clinical Trials
Clinical Trials Basics
Translational Research Units
Recommended Resources

Cancer Clinical Trials

Site: Hematologic/Blood-Related

The most recent listing of current clinical trials for hematologic and blood-related cancers — including blood and marrow transplant/BMT, leukemia, non-Hodgkins lymphoma, Hodgkin's disease/lymphoma and multiple myeloma — appears below. Should you be interested in learning more about any of these clinical trials, please use our Contact Us form.
 

Site: Hematologic/Blood-Related
(Includes Blood and Marrow Transplant/BMT,
Leukemia, Non-Hodgkins Lymphoma,
Hodgkin's Disease/Lymphoma,
Lymphoma and Multiple Myeloma)

Protocol ID    Title

SWOG 1117    A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Keywords: Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

ECOG 1411    Intergroup Randomized Phase II Four Arm Study In Patients > 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB - R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV-R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB-LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RB- LR)

Keywords: Previously Untreated Mantle Cell Lymphoma

Industry-C16010    A Phase 3, Randomized, double-Blind Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Site laceboversus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma

Keywords: Relapsed and/or Refractory Multiple Myeloma

FHCRC-2241    Sequential Autologous HCT/ Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Keywords: High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

ECOG 3903    Ancillary Laboratory Protocol for the Collection of Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders

Keywords: Leukemia or Related Hematologic Disorders

RDCRN 6501    Longitudinal Study of Immune Mediated Disorders after Allogeneic Hemotopoietic Cell Transplantation

Keywords: Allogeneic Hemotopoietic Cell Transplantation

In-House-GVHD    Acquisitions of Graft v. Host Disease Sample in Pre-Clinical Studies

Keywords: Graft v. Host Disease

In-House    Laboratory Studies of Iron Metabolism in Blood Cells from Patients with Hematochromatosis

Keywords: patients with hematochromatosis

In-House: Pre-Clinical
Vaccine for MM
   Pre-Clinical Studies on Vaccine Derived From Patient-Derived Myeloma Cells

Keywords: Multiple Myeloma

E2903    Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia

Keywords: Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia

E1906    A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia

Keywords: Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia

E2905    Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid ®) Alone in Combination with Epoetin Alfa (Procrit ®) in Subjects with Low- or Intermediate -1 Risk MDS and Symptomatic Anemia

Keywords: Low- or Intermediate -1 Risk MDS and Symptomatic Anemia

AT7519M/0004    A Phase I/II Open-Label Multicenter Study of AT7519M Alone and in Combination with Bortezomib in Patients with Previously Treated Multiple Myeloma

Keywords: Patients with Previously Treated Multiple Myeloma

CTN 0702    A Trial of Single Autologous Transplant with or without Consolidation Therapy vs. Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma

Keywords: Patients with Multiple Myeloma

CTN 0901    A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intesnsity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

Keywords: Myelodysplastic Syndrome or Acute Myeloid Leukemia

E2906    Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years)

Keywords: Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years)

C05013    An Open-Label, Randomized, Phase II Study to Assess the Effectiveness of RCHOP with or without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma

Keywords: Diffuse Large B-Cell Lymphoma

In-house    Phase I-II Study Using Tocilizumab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

Keywords: Refractory Acute Graft Versus Host Disease

E2408    A 3 Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Rituximab vs. BR Followed by Lenalidomide/ Rituximab in High Risk Follicular Lymphoma

Keywords: High Risk Follicular Lymphoma

Industry — Multiple Myeloma    Phase I/II, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/ Refractory Multiple Myeloma

Keywords: Relapsed or Relapsed/ Refractory Multiple Myeloma

FH-2230.00    A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA Haploidentical Hematopoietic Cell Transplantation

Keywords: Nonmyeloablative, HLA Haploidentical Hematopoietic Cell Transplantation

FH-2448.00    A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multicenter Trial

Keywords: Donor Hematopoietic Cell Transplantation

S0805    Phase II Study of Combination fo Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)

Keywords: Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

S1106    A Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. Bendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients greater than or equal to 65 years of Age with Previously Untreated Mantle Cell Lymphoma

Keywords: Previously Untreated Mantle Cell Lymphoma

In-house Fenske-TC99    Development of 99mTechnetium scanning as a quantitative in vivo assay to predict chemotherapy drug resistance and clinical outcome in lymphoma patients.

Keywords: lymphoma

CTN 0801    A Phase II/III Randomized, Multi-center Trial Comparing Sirolimus plus Prednisone and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host-Disease

Keywords: Graft-versus-Host-Disease

RDCRN 6503    Targeted Therapy of Bronchiolitis Obliterans Syndrome

Keywords: Bronchiolitis Obliterans Syndrome

RDCRN 6502    A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation

Keywords: Cutaneous Sclerosis

ON 01910.Na    A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72 hour Continuous Intravenous Infusion Every Other Week In Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After or Refractory to, or Intolerant to Azacitadine or Decitabine

Keywords: Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After or Refractory to, or Intolerant to Azacitadine or Decitabine

Industry — Acute Myeloid Leukemia    A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Keywords: Newly Diagnosed Acute Myeloid Leukemia, Elderly Patients

WON HO10407    A Phase II Study of Bortezomib and Temsirolimus for Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Keywords: Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Industry — CLL 0115    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Keywords: Previously Treated Chronic Lymphocytic Leukemia

Industry — CLL 0116    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL 101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Keywords: Previously Treated Chronic Lymphocytic Leukemia

Industry — CLL 0117    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL 101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Keywords: Previously Treated Chronic Lymphocytic Leukemia

Industry — MDS or AML    A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-Label, Part 2: Randomized, Double-Blind, Part 3: extension)

Keywords: Thrombocytopenic with Myelodysplastic Syndromes or Acute Myeloid Leukemia

Industry — polycythemia vera    Polycythemia Vera Symptom Trial Evaluating Ruxolitinib versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes (the RELIEF study)

Keywords: Polycythemia Vera

Industry — Transplant, MM    Ligand: A Phase IIb, Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan HCl for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Keywords: Multiple Myeloma Patients Undergoing Autologous Transplantation

Industry — Myeloproliferative Neoplasms    A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

Keywords: Myeloproliferative Neoplasms

Industry — Amyloidosis    A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Keywords: Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

University of Michigan — AML    Multi-center single arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for non-remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) regimen

Keywords: Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML)

Industry — AML    Celator CLTR0310-301: Celator 301: Phase III, Multicenter, Randomized, Trial Of CPX-351(cytarabine:daunorubicin) Liposome Injection Versus Cytarabine And Daunorubicin In Patients 60-75 Years Of Age With Untreated High Risk (Secondary) AML

Keywords: Untreated High Risk (Secondary) AML

 

 

Last Review Date: April 29, 2013

Online Editor(s): Shannon Krause

e-Newsletters

Monthly articles about the health topics of your choice!

Sign Up Today Sign Up Today

Log In to My Froedtert Log In to My Froedtert

Related Information

Blood and Marrow Transplant Program Overview

Roads Lead to Froedtert

Blood and Marrow Transplant Program Highlights

Living On Borrowed Strength

Small Stones Wellness Center

Powerful Brain Imaging Technology Invented Here

More >>

Quick Links

Register for Classes/Events

Find a Doctor

Get Directions

Request an Appointment

Pay Your Bill

e-Newsletter Sign-Up

Make a Donation

Gift Shop

Printer Icon
Printer Friendly
Envelope Icon
Send to a Friend
© 2013 Froedtert & The Medical College of Wisconsin
9200 W. Wisconsin Ave.
Milwaukee, WI 53226
Privacy | Security | Editorial Policy | Terms and Conditions | Accessibility | Site Index